These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30625040)

  • 1. Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
    Arasu VA; Miglioretti DL; Sprague BL; Alsheik NH; Buist DSM; Henderson LM; Herschorn SD; Lee JM; Onega T; Rauscher GH; Wernli KJ; Lehman CD; Kerlikowske K
    J Clin Oncol; 2019 Apr; 37(12):954-963. PubMed ID: 30625040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Background Parenchymal Enhancement on Contrast-Enhanced Mammography.
    Karimi Z; Phillips J; Slanetz P; Lotfi P; Dialani V; Karimova J; Mehta T
    AJR Am J Roentgenol; 2021 Feb; 216(2):340-348. PubMed ID: 32755162
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of Background Parenchymal Enhancement on Cancer Risk Across Different High-Risk Patient Populations Undergoing Screening Breast MRI.
    Sippo DA; Rutledge GM; Burk KS; Mercaldo SF; Dontchos BN; Edmonds CE; Lehman CD
    AJR Am J Roentgenol; 2019 Mar; 212(6):1412-1418. PubMed ID: 30888867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated rating of background parenchymal enhancement in MRI of extremely dense breasts without compromising the association with breast cancer in the DENSE trial.
    Wang H; H M van der Velden B; Verburg E; Bakker MF; Pijnappel RM; Veldhuis WB; van Gils CH; Gilhuijs KGA
    Eur J Radiol; 2024 Jun; 175():111442. PubMed ID: 38583349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between Background Parenchymal Enhancement on High-risk Screening MRI and Future Breast Cancer Risk.
    Grimm LJ; Saha A; Ghate SV; Kim C; Soo MS; Yoon SC; Mazurowski MA
    Acad Radiol; 2019 Jan; 26(1):69-75. PubMed ID: 29602724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
    Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
    Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
    Watt GP; Sung J; Morris EA; Buys SS; Bradbury AR; Brooks JD; Conant EF; Weinstein SP; Kontos D; Woods M; Colonna SV; Liang X; Stein MA; Pike MC; Bernstein JL
    Breast Cancer Res; 2020 Dec; 22(1):138. PubMed ID: 33287857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
    Sung JS; Corben AD; Brooks JD; Edelweiss M; Keating DM; Lin C; Morris EA; Patel P; Robson M; Woods M; Bernstein JL; Pike MC
    Breast Cancer Res Treat; 2018 Nov; 172(2):487-496. PubMed ID: 30140962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated surgeries in invasive lobular breast cancer with preoperative MRI: Role of additional carcinoma in situ and background parenchymal enhancement.
    Preibsch H; Richter V; Bahrs SD; Hattermann V; Wietek BM; Bier G; Kloth C; Blumenstock G; Hahn M; Staebler A; Nikolaou K; Wiesinger B
    Eur J Radiol; 2017 May; 90():181-187. PubMed ID: 28583631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study.
    Hruska CB; Geske JR; Conners AL; Whaley DH; Rhodes DJ; O'Connor MK; Carter RE; Scott CG; Vachon CM
    AJR Am J Roentgenol; 2021 May; 216(5):1193-1204. PubMed ID: 32755210
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of Background Parenchymal Enhancement at Contrast-enhanced Spectral Mammography and Breast MR Imaging.
    Sogani J; Morris EA; Kaplan JB; D'Alessio D; Goldman D; Moskowitz CS; Jochelson MS
    Radiology; 2017 Jan; 282(1):63-73. PubMed ID: 27379544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualitative assessments of density and background parenchymal enhancement on contrast-enhanced spectral mammography associated with breast cancer risk in high-risk women.
    Xu C; Jiang M; Lin F; Zhang K; Xie H; Lv W; Ji H; Mao N
    Br J Radiol; 2023 Aug; 96(1148):20220051. PubMed ID: 37227804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?
    Dontchos BN; Rahbar H; Partridge SC; Korde LA; Lam DL; Scheel JR; Peacock S; Lehman CD
    Radiology; 2015 Aug; 276(2):371-80. PubMed ID: 25965809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Background parenchymal enhancement at breast MR imaging and breast cancer risk.
    King V; Brooks JD; Bernstein JL; Reiner AS; Pike MC; Morris EA
    Radiology; 2011 Jul; 260(1):50-60. PubMed ID: 21493794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Breast Density With Breast Cancer Risk Among Women Aged 65 Years or Older by Age Group and Body Mass Index.
    Advani SM; Zhu W; Demb J; Sprague BL; Onega T; Henderson LM; Buist DSM; Zhang D; Schousboe JT; Walter LC; Kerlikowske K; Miglioretti DL; Braithwaite D;
    JAMA Netw Open; 2021 Aug; 4(8):e2122810. PubMed ID: 34436608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Background Parenchymal Enhancement at Contrast-Enhanced Spectral Mammography (CESM) as a Breast Cancer Risk Factor.
    Sorin V; Yagil Y; Shalmon A; Gotlieb M; Faermann R; Halshtok-Neiman O; Sklair-Levy M
    Acad Radiol; 2020 Sep; 27(9):1234-1240. PubMed ID: 31812577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of background parenchymal echogenicity on breast ultrasound: Correlation with mammographic breast density and background parenchymal enhancement on magnetic resonance imaging.
    Ko KH; Jung HK; Kim I
    Medicine (Baltimore); 2017 Aug; 96(33):e7850. PubMed ID: 28816987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?
    Bermot C; Saint-Martin C; Malhaire C; Sebbag-Sfez D; Mouret-Fourme E; Carton M; Thibault FE
    Eur J Radiol; 2018 Dec; 109():171-177. PubMed ID: 30527300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-Dimensional Quantitative Validation of Breast Magnetic Resonance Imaging Background Parenchymal Enhancement Assessments.
    Ha R; Mema E; Guo X; Mango V; Desperito E; Ha J; Wynn R; Zhao B
    Curr Probl Diagn Radiol; 2016; 45(5):297-303. PubMed ID: 27039221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could parenchymal enhancement on contrast-enhanced spectral mammography (CESM) represent a new breast cancer risk factor? Correlation with known radiology risk factors.
    Savaridas SL; Taylor DB; Gunawardana D; Phillips M
    Clin Radiol; 2017 Dec; 72(12):1085.e1-1085.e9. PubMed ID: 28870431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.